Seattle biotech using a non-viral lipid delivery platform to deliver gene-directed payloads that destroy senescent cells.
Clinical-stage developer of small-molecule senolytics that selectively clear pathologic senescent cells driving age-related disease.
Including Funding rounds + valuations, Founders + executives, Products + tech stack, Headcount + HQ, Status timeline, and Roster connections.
Already subscribed? Sign in →